Brian F Volkman

Plain English
This study explored how certain changes in proteins, known as mutations, influence predictions made by a computer program called AlphaFold, which helps predict protein structures. Researchers created a tool called CAAT that can pinpoint specific amino acids in proteins that significantly impact these predictions. They found that CAAT could effectively identify which amino acid modifications would lead to more accurate predictions, making the search for beneficial mutations easier. Who this helps: This benefits scientists studying protein structures and developing new treatments for diseases.

Plain English
This study focused on understanding how a specific protein, called the ACKR3 receptor, works differently from typical proteins targeted by drugs. Researchers discovered that ACKR3 is activated in an unusual way that doesn't follow the usual rules, finding that changes in the shape of the outer part of the receptor play a key role in its activity. This research reveals new possibilities for designing medications that can better target hard-to-reach proteins in the body. Who this helps: This helps drug developers and researchers working on new treatments.

Plain English
This research paper examines XCL1, a special protein that plays a key role in guiding immune cells and has two different shapes that allow it to perform different tasks. It can attract certain immune cells but also has the ability to fight off infections. Understanding the changing nature of XCL1 is important because it can influence how we develop vaccines and might have new roles in brain health. Who this helps: This helps researchers and vaccine developers in improving treatments and therapies for patients.

Plain English
This study looked at how a receptor called ACKR2 interacts with different types of chemokines, which are molecules important for the immune system. Researchers found that ACKR2 can also bind to certain CXC chemokines, not just the CC chemokines it was previously thought to handle. Specifically, they identified four CXC chemokines (CXCL5, CXCL10, CXCL11, and CXCL12) that connect with ACKR2, showing its broader role in regulating immunity than previously understood. Who this helps: This research benefits doctors and scientists working on immune-related conditions and treatments.

Plain English
This study looked at how certain proteins, called chemokines, interact with cell surface receptors to guide cell movement in the body. Researchers found that these interactions can be both specific and broad, depending on shared and unique features of the proteins involved. They identified key elements that determine how these proteins recognize each other, which could help create new treatments for diseases. Who this helps: This helps patients needing better immune therapies and cell treatments.

Plain English
This study investigated how certain proteins called chemokines can kill bacteria without leading to antibiotic resistance. The researchers found that chemokines that bind to specific molecules in bacterial membranes, known as phosphatidylglycerol and cardiolipin, are especially effective at killing bacteria, working even better than a known antibiotic peptide. Importantly, bacteria did not develop resistance to these chemokines, indicating a potential new way to combat infections. Who this helps: This research benefits patients by offering new strategies to treat bacterial infections without contributing to antibiotic resistance.

Plain English
This study looks at a new type of antibody called nanobodies, which are useful for researching and developing drugs that target G protein-coupled receptors (GPCRs). Researchers found that these extracellular nanobodies can not only help stabilize GPCR structures but also change how these receptors work in the body. This is important because it opens the door to new ways to develop treatments for a variety of diseases by better understanding and manipulating GPCR activity. Who this helps: Patients who may benefit from new therapies for conditions affected by GPCRs.

Plain English
Researchers studied a receptor called ACKR3, which is involved in regulating certain signals in the body and is found to be more active in several diseases. They discovered that using specialized proteins, called nanobodies, to block the usual activity of ACKR3 could reduce its unwanted effects, like cancer cell movement, by decreasing its interaction with other signaling molecules. This finding is important because it opens up new ways to develop treatments that target ACKR3's activity in various health conditions. Who this helps: This helps patients with diseases associated with ACKR3, particularly cancer patients.

Plain English
In this study, researchers looked at a new treatment called CCL20LD, designed to target a specific protein involved in immune response without causing unwanted side effects. They found that giving this treatment daily for 14 days did not lead to weight loss or immune issues, and only caused minor effects on certain immune responses at higher doses. This is important because it shows that CCL20LD could be a safe option for treating diseases related to the CCL20-CCR6 pathway, such as psoriasis or psoriatic arthritis. Who this helps: This helps patients with psoriasis and psoriatic arthritis.

Plain English
This study focused on a unique plant system that helps them detect a hormone called abscisic acid (ABA). Researchers developed a new module that improves how plants sense certain chemicals, showing that their system can detect low levels of harmful pesticides with great accuracy. Specifically, the new system can sense these chemicals at levels as low as nanomolar, which is very sensitive. This advancement is important because it could allow for better monitoring of harmful substances in the environment and support the development of new biosensors for agriculture. Who this helps: This benefits farmers and environmental scientists looking to monitor plant health and pesticide levels.

Plain English
This study looked at a special kind of antibody called a nanobody that targets a specific receptor in the body known as ACKR3, which is a type of G protein-coupled receptor (GPCR). Researchers found that a unique part of the nanobody, called an extended CDR3 loop, is crucial for it to bind effectively to ACKR3, making it a potential tool for drug development. Understanding how these nanobodies work helps improve the design of new therapies for conditions related to GPCRs, which are important targets for many medications. Who this helps: This benefits patients needing better treatments for diseases linked to GPCRs.

Plain English
This study examined how certain proteins called chemokines can kill bacteria by attaching to specific lipids in the bacterial membrane. Researchers found that chemokines bind to two types of lipids—phosphatidylglycerol and cardiolipin—allowing them to effectively kill bacteria at a higher strength than another common antibacterial protein. Importantly, bacteria did not develop resistance to these chemokines, which makes them promising candidates for new types of antibiotics. Who this helps: This research benefits patients facing infections, particularly those with antibiotic-resistant bacteria.

Plain English
This study looked at two proteins, CCR1 and CCR5, and how they react to certain signals called ligands. The researchers found that CCR5 needs specific modifications (called O-glycosylation) to effectively respond to these signals, while CCR1 does not. When they adjusted the acidity of CCR5, it became less reliant on these modifications, and adding certain basic peptides made the responses even stronger. This research is important because it helps us understand how these receptors work, which can lead to better treatments for conditions where these proteins play a role, such as in inflammation and immune responses. Who this helps: This benefits patients with immune-related conditions.

Plain English
Researchers studied how a specific receptor called XCR1 interacts with a chemokine named XCL1, which is important for activating certain immune cells that help fight cancer. They found detailed information about how XCL1 fits into XCR1, showing that this precise interaction is crucial for triggering the receptor's activity. This understanding could lead to new cancer treatments and vaccines that improve how these immune cells present disease markers, enhancing the body’s ability to recognize and attack tumors. Who this helps: This helps patients undergoing cancer treatment by potentially improving immunotherapies.

Plain English
This study examined how an unusual receptor, called ACKR3, behaves in the body and how it might affect diseases, especially breast cancer. Researchers found that blocking the natural activity of ACKR3 reduced its involvement in cancer cell movement, suggesting that this receptor might play a role in cancer progression. These findings highlight the potential for new treatments that target ACKR3 to help manage diseases where this receptor is overactive. Who this helps: This benefits patients with breast cancer and other related disorders.

Plain English
The researchers studied a specific protein called CCL22, which is linked to inflammatory conditions like eczema and asthma. They developed a new type of inhibitor, a cyclic peptide, that can effectively bind to CCL22 and stop its activity, showing strong effectiveness with a measurement known as nanomolar affinity, meaning it works very well even at low concentrations. This is important because it opens up new possibilities for treating inflammatory diseases by targeting CCL22 more precisely. Who this helps: This helps patients suffering from inflammatory diseases like asthma and eczema.

Plain English
This study examined the effects of a protein known as CXCL12(3-68), a shorter version of a cytokine important for bone healing. The researchers found that CXCL12(3-68) not only stopped bone-forming stem cells from growing and moving but also caused them to age prematurely. This matters because it reveals how a specific protein change can affect bone health, which has wider implications for conditions like osteoporosis and could influence treatments for various diseases. Who this helps: This helps patients with osteoporosis and other bone-related conditions.

Plain English
This study focused on a protein called SRCP1, which helps prevent the harmful clumping of proteins that can lead to certain diseases like Huntington's disease. The researchers found that SRCP1 not only plays a key role in stopping these clumps but also identified specific parts of its structure that are important for this action. They discovered that SRCP1 can effectively inhibit protein aggregation in various situations, potentially leading to new treatments for polyglutamine diseases. Who this helps: This research benefits patients suffering from polyglutamine diseases, as well as the doctors treating them.

Plain English
This study focused on developing new drugs that target a specific protein, CCL28, which plays a role in suppressing the immune response in tumors. Researchers screened over 2,600 small chemical compounds and found thirteen that could potentially bind to CCL28, with two of those compounds capable of attaching at the same time. This is important because it may lead to more effective treatments that can enhance the immune response against tumors. Who this helps: This helps patients with cancer by improving immunotherapy options.

Plain English
This study developed a new test to measure a modified version of a protein called CCL20, which could help treat psoriasis and psoriatic arthritis. The researchers found a specific antibody that can clearly differentiate the modified protein from its natural form, allowing accurate tracking of its levels in the blood of treated mice. This is important because measuring this protein can help scientists understand how well the new treatment works and its potential side effects. Who this helps: This helps patients with psoriasis and psoriatic arthritis by supporting the development of more effective treatments.

Plain English
This study focused on creating new small beta barrel proteins, which are tiny protein structures known for their diverse functions but challenging to design. Researchers successfully designed several types of these proteins using advanced computer methods, achieving highly stable structures with less than 2.4 angstroms of deviation from their intended models. This is important because it opens up new possibilities for designing proteins that can target specific molecules in medicine and biotechnology. Who this helps: This benefits researchers and developers working on new therapies and treatments.

Plain English
This study looked at a specific protein called ACKR1, which plays a significant role in how cells communicate during inflammation and cancer progression. Researchers found that targeting ACKR1 could help develop new treatments for cancer and other diseases, as it regulates important chemical signals in the body. This is important because it could lead to better therapies that are less likely to cause side effects, increasing the effectiveness of cancer treatments. Who this helps: This helps patients battling cancer and related diseases.

Plain English
This study looked at 86 different mutations in a gene called KRAS, which is important for cancer and other diseases. Researchers found that these mutations lead to changes in the protein's structure, affecting how it behaves in the body. This understanding is important because it helps explain how various mutations, not just the commonly studied ones, can influence disease processes and treatment options. Who this helps: This benefits patients with cancer and genetic disorders, as well as doctors seeking to tailor treatments based on specific mutations.

Plain English
This study looked at special types of proteins called metamorphic proteins, which can change into different structures and serve various functions. Researchers found that these proteins, like those in the NusG family and the chemokine XCL1, are not just odd exceptions but important adaptations that have evolved to help organisms survive and thrive. They discovered that a wide range of protein sequences can actually support this versatile folding ability, suggesting that such proteins are likely more common and important for biological functions than we previously recognized. Who this helps: This research benefits scientists and healthcare professionals studying protein functions and diseases.

Plain English
This study looked at a protein pair, CCL20 and its receptor CCR6, that helps white blood cells move to areas of inflammation in people with psoriasis and psoriatic arthritis. Researchers reviewed over 70 studies and found that targeting the CCL20-CCR6 pathway has shown promise in experiments with animals, which may lead to new treatments in the future. Understanding this mechanism could also have implications for other autoimmune diseases. Who this helps: This helps patients with psoriasis, psoriatic arthritis, and potentially other autoimmune conditions.

Plain English
Researchers studied proteins that can change their shape in response to environmental signals, much like how computer transistors work. They successfully engineered special "hinge" proteins that have two stable forms; one when there's no binding molecule present and another when it is. The study found that these proteins can switch between their two shapes with precision, demonstrating that their design is accurate at the atomic level. Who this helps: This benefits scientists working on drug design and therapies targeting specific diseases.

Plain English
This study focused on creating and testing a system to purify two important human proteins, SR-B1 and CD36, which help the body manage fats and cholesterol. The researchers successfully produced these proteins in a lab using insect cells, confirming they work properly for their intended roles, such as binding with cholesterol. This research is crucial because it provides the necessary tools for future studies that could lead to better understanding and treatment of heart disease. Who this helps: This helps researchers and healthcare professionals studying heart disease and cholesterol management.

Plain English
This study explores how changes in the EHMT1 gene, which is important for proper development and is linked to Kleefstra syndrome and some cancers, affect the gene's function. The researchers examined 97 specific gene changes and found that harmful variants mainly occur near areas critical for the gene's activity. This improved understanding helps with diagnosing Kleefstra syndrome and advancing future research. Who this helps: This benefits patients with Kleefstra syndrome and their doctors by improving diagnosis and treatment options.

Plain English
This study explored 86 different mutations in the KRAS gene, which is crucial for understanding various cancers and some inherited conditions. The researchers found that these mutations lead to unique changes in the structure and function of the KRAS protein, affecting how it interacts with other molecules. This work is important because it reveals new details about the effects of these mutations beyond the commonly studied ones, offering insights that existing genomic tools can't provide. Who this helps: This helps doctors and researchers who treat cancer patients and those with related genetic conditions.

Plain English
This study focused on a method called fragment-based drug discovery (FBDD) that helps scientists find small compounds able to attach to specific proteins in the body, which can lead to new medications. The researchers created a detailed process for screening a library of less than 10,000 potential drug compounds, ensuring that proteins remain stable during the testing and using advanced tools for accurate measurements. As a result, they successfully identified new molecules that bind strongly to various target proteins, which can advance the development of targeted therapies. Who this helps: This benefits researchers and pharmaceutical companies working on new drug developments.

Plain English
This study looked at different genetic changes in a gene called EHMT1, which is important for baby development and is linked to Kleefstra syndrome and some cancers. The researchers analyzed 97 specific changes in the EHMT1 gene and found that harmful changes were mostly located near key areas of the gene responsible for its activity. This new method helps better understand how these genetic variants affect health, which can improve diagnosis and treatment options for patients. Who this helps: Patients with Kleefstra syndrome and their doctors.

Plain English
This study examined genetic changes in the KMT2C gene, which are linked to Kleefstra Syndrome type 2 (KLEFS-2), a condition that leads to intellectual disabilities and other developmental issues. Researchers found that different types of genetic variants in KMT2C disrupt its normal function in various ways, affecting the structure and behavior of the associated protein. Understanding these mechanisms is crucial for developing better treatments and interventions for individuals affected by this genetic disorder. Who this helps: This helps patients with Kleefstra Syndrome type 2 and their families.

Plain English
This study focused on understanding how a protein called DOT1L, which is linked to blood cancer, interacts with other proteins involved in this process. Researchers found that certain parts of DOT1L frequently interact with a molecule called SAM, revealing that the way DOT1L moves and behaves is more complex than previously thought. This information is crucial for developing new treatments for blood cancers and understanding how these molecular interactions contribute to the disease. Who this helps: This benefits patients with blood cancers and the doctors treating them.

Plain English
This study examined the structure of a protein called CCL19, which helps immune cells move around the body and is involved in cancer spread. Researchers found that the shape and certain details of CCL19 are crucial for how it interacts with a receptor (CCR7) on cells; for instance, they identified new areas important for binding that could be targeted by new drugs to prevent cancer metastasis. Understanding these interactions can lead to better treatments for cancer. Who this helps: This research benefits cancer patients by paving the way for new therapies to stop cancer spread.

Plain English
This study looked at how specific parts of a protein called CCR7 and its related chemokines (signaling molecules) affect the behavior of immune cells, particularly how they move to lymph nodes. The researchers discovered that a specific fragment of the CCL21 chemokine (called C21TP) can increase the effectiveness of two related chemokines, CCL19 and CCL21, in activating immune responses. For example, a modified version of CCL19 was found to be 22 times more effective than the original version in activating CCR7 without needing the booster fragment. Who this helps: This benefits patients by potentially improving immune responses in treatments like vaccines or immunotherapies.

Plain English
This study examined different versions of a specific protein made by the human cytomegalovirus (HCMV), focusing on how they interact with immune system cells called neutrophils. Researchers found that one version (vCXCL1GT5) specifically activates a receptor called CXCR2, leading to the movement of neutrophils, just like another version (vCXCL1GT1) does, although vCXCL1GT1 works with two receptors. Understanding these interactions is important because it could help explain why HCMV has so many different types, which is crucial for developing better treatments for infections, especially in patients with weakened immune systems. Who this helps: This research helps patients with weakened immune systems, such as those with organ transplants or HIV.

Plain English
This study examined how certain molecules from ovarian tumors affect T cells, which are crucial for fighting cancer. Researchers found that a molecule called sphingosine-1-phosphate (S1P), carried by tiny vesicles from the tumor, can weaken T cells, causing them to stop working effectively. Blocking the production of S1P not only helped T cells attack tumors better but also made a cancer treatment (anti-PD-1 antibody) even more effective, reducing tumor size and spread in lab tests. Who this helps: Patients with ovarian cancer can benefit from better treatments that enhance their immune response.

Plain English
This research focused on metamorphic proteins, which are unique because they can change their shapes and functions while being made up of the same building blocks. The study found that up to 4% of proteins might have this ability to switch structures, which can lead to new medical treatments and technologies. Understanding and creating these proteins could improve therapies for various diseases and lead to new tools in medical science. Who this helps: This benefits patients and researchers looking for innovative treatments and diagnostic tools.

Plain English
This study examined mutations in the KDM6A gene, which is linked to a rare genetic disorder and various cancers. Researchers analyzed 197 mutations and found that 136, or 69%, were damaging to the gene, significantly reducing the number of mutations classified as uncertain from over 40% to just 14.7%. Understanding these mutations better helps improve clinical diagnosis and could lead to new treatments targeting specific mutations associated with diseases. Who this helps: Patients with KDM6A mutations and their doctors.

Plain English
This study looked at two versions of a protein called CXCR3, which helps immune cells move and activate in the body: CXCR3-A and CXCR3-B. Researchers found that the extra piece on CXCR3-B changes how it works, making it unable to connect with certain signaling pathways but still able to take in specific molecules. These findings are important because understanding how these two versions function differently can help improve therapies targeting immune responses. Who this helps: This benefits researchers and doctors working on treatments for immune-related diseases.

Plain English
This study focused on creating a new type of biosensor using a plant hormone receptor called PYR1, which can be quickly adapted to detect different molecules. Researchers successfully developed 21 sensors that can identify small amounts (from nanomolar to micromolar concentrations) of various compounds, including different cannabinoids and organophosphates. This advancement is important because it allows for the rapid creation of sensitive detection tools for a wide range of biological applications. Who this helps: This benefits researchers and industries needing efficient testing methods for various substances.

Plain English
This study examined how a specific type of receptor in our cells, called the atypical chemokine receptor (ACKR3), recruits a protein known as β-arrestin, which plays a key role in various cellular processes. The researchers found that changes in the receptor's structure—specifically in its binding area for signals and its connection site for β-arrestin—are important for this recruitment. They discovered that certain mutations in the receptor hindered this process, highlighting how these structural changes influence how the receptor works. Who this helps: This benefits researchers and drug developers working on treatments that target GPCRs, which are crucial for many diseases.

Plain English
This study looked at a protein called PBRM1, which plays a role in cancer, especially prostate cancer, where it can help tumors grow by affecting cell movement and immune response. Researchers tested nearly 2,000 small chemical compounds to find ones that specifically target PBRM1 and discovered 17 promising candidates, with the strongest ones being very effective at low concentrations. These new compounds can block PBRM1's activity and slow down the growth of prostate cancer cells that rely on this protein. Who this helps: Patients with prostate cancer.

Plain English
This study looked at a protein called XCL1, which can change its shape and has the ability to kill fungi. Researchers found that both shapes of XCL1 can kill fungi, but they do it in different ways: one shape disrupts the fungal cell membrane, while the other does not. This ability to switch shapes might help XCL1 be more effective against drug-resistant fungal infections while minimizing damage to nearby tissues. Who this helps: Patients with serious fungal infections and doctors treating these conditions.

Plain English
This research studied how certain proteins in human cells interact with each other to help the HIV virus leave infected cells and spread. The team found that one specific interaction between AMOT and NEDD4L proteins is especially strong, which is crucial for HIV to successfully bud off from the cell, with AMOT PPxY1 binding most effectively to NEDD4L WW3. This understanding is important because it could lead to new treatments targeting these interactions to hinder HIV's ability to infect more cells. Who this helps: Patients living with HIV.

Plain English
This study focused on how aging affects specific small molecules called microRNAs (miRNAs) in human stem cells that help form bone. Researchers found that aging leads to changes in the expression of 102 miRNAs, with one, miR-29b-1-5p, becoming significantly more active. This miRNA negatively impacts the ability of stem cells to produce bone, which is important for understanding why older adults are more prone to bone issues like osteoporosis. Who this helps: This helps patients, especially older adults at risk of osteoporosis.

Plain English
This study looked at how a molecule called CXCL12 interacts with different receptors in the body, specifically focusing on its dimeric form, which consists of two linked CXCL12 molecules. Researchers found that the dimeric form of CXCL12 binds strongly to a receptor named ACKR1, while the single (monomeric) form does not bind nearly as effectively. This discovery is important because it shows that the dimeric form of CXCL12 has a unique role in regulating various biological functions, which could impact how the body responds to diseases. Who this helps: This benefits patients and researchers studying immune responses and cancer treatments.

Plain English
Researchers studied a new compound called antabactin (ANT), which blocks the effects of a plant hormone called abscisic acid (ABA) that can inhibit seed germination. They created a large number of variations of a previously known compound and found that ANT works effectively, with a very strong ability to bind to ABA receptors (about 400 to 1,700 picomolar). This is important because ANT can speed up seed germination in crops like tomato and barley, potentially improving agricultural yields by overcoming the limitations caused by ABA. Who this helps: Farmers and agricultural scientists looking to enhance crop production.

Plain English
In this study, researchers investigated how a specific peptide from a protein called CCL21 enhances the ability of CCL21 to attract immune cells to lymph nodes, which is important for mounting an immune response. They found that this peptide, known as C21TP, can increase CCL21's effectiveness by up to 25 times for recruiting immune cells and about 100 times for signaling through its receptor, CCR7. This discovery is significant because it reveals a new way to enhance immune function, which could inform therapies for conditions like infections or cancer. Who this helps: This benefits patients needing improved immune responses, such as those with cancer or infections.

Plain English
Researchers studied a protein called CXCL12, which plays a key role in immune function and is linked to several cancers and inflammatory diseases. They found that a new group of compounds, called trisubstituted 1,3,5-triazines, can effectively bind to CXCL12, improving their potential as treatments. Out of fifty compounds developed, they created more effective and soluble options for future drug development. Who this helps: This research helps drug developers and patients with cancer or inflammatory diseases.